Maximum Strength Comtrex
Failed Impurities/Degradation:Specifications:Unknown degradant found during stability testing.
Class III means the product is unlikely to cause harm but violates FDA labeling or manufacturing rules. These are the recalls you rarely hear about; pharmacies usually just swap the affected lot.
1,716 recalls, newest first.
Failed Impurities/Degradation:Specifications:Unknown degradant found during stability testing.
Failed Impurities/Degradation:Specifications:Unknown degradant found during stability testing.
Failed Impurities/Degradation:Specifications:Unknown degradant found during stability testing.
Failed Impurities/Degradation:Specifications:Unknown degradant found during stability testing.
Failed Dissolution Specifications: Routine stability testing at the 12-month interval yielded an out-of-specification (OOS) result for dissolution testing.
Failed Impurity/Degradation Specifications; out of specification value for impurity Nitrophenylpuridine Derivative (NPP-D)
Subpotent Drug: the active ingredient, fluocinolone acetonide, was found to be subpotent during the firm's routine testing.
Subpotent; 24 month stability test station
Discoloration: This recall is being carried out due to a yellow to brown discolored Amoxicillin powder on the inner foil seal of the bottles.
Labeling: Incorrect or Missing Lot and/or Expiration date; The Lot and/or Expiration date on the tube may not be legible in this lot.
Labeling: Label Error on Declared Strength: Incorrect strength on side display panel of label
Subpotent; Cetylpyridinum Chloride
Chemical Contamination: Topiramate Tablets is being recalled due to complaints related to an off - odor. described as moldy, musty or fishy in nature.
Chemical Contamination: Pravastatin Sodium Tablets isbeing recalled due to complaints related to an off-odor described as moldy, musty or fishy in nature.
Chemical Contamination: Gabapentin Sodium tablets is recalled due to complaints related to an off - odor described as moldy, musty or fishy in nature.
Presence of Precipitate; white substance confirmed as Guaifenesin, an active ingredient was observed in some bottles. If the product is shaken or warmed the white particles goes into the solution.
Labeling: Incorrect or Missing Lot and/or Exp Date: Lorazepam Lot # L-04009
Failed USP Dissolution Test Requirements: Out-of-specification dissolution results at the 8 hour stability testing point.
CGMP Deviation; cotton coil is missing in some packaged bottles
Labeling Illegible: There is a possibility that the bottle labels do not contain the strength of the product as well as other printing details.
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
SubPotent Drug: The firm discovered out of specification results for assay and the extended investigation revealed the potential for lower weight tablets.
Subpotent Drug: Product did not conform to the 18-month stability test specification for active Free Benzocaine.
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing
Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing